In contrast to previously published studies on SMAD4 as a prognostic biomarker in resected PC [10,11,15,16,17,18], we did not detect a negative prognostic impact of SMAD4 loss on OS or PFS in our study population. This evidence concerns the gene SMAD4 and pachyonychia congenita.